Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVO
Post# of 52
(Total Views: 326)
Posted On: 06/26/2018 7:39:33 PM
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Focusing On Innovative Drug Delivery Technologies
- Pivot offers unique proprietary drug delivery platform technologies
- Company has a strong intellectual property (IP) portfolio for the formulation and delivery of cannabinoids
- Company acquires licensing rights to patented Trivair™ nasal and pulmonary drug delivery system, also signs exclusive manufacturing agreement with Bio V Pharma
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is a biopharmaceutical company based in Vancouver, British Columbia. Pivot engages in the development and commercialization of premium cannabinoid-based nutraceuticals and pharmaceuticals. It does so utilizing unique drug delivery platform technologies. Pivot Pharmaceuticals’ wholly-owned medical cannabis products division is Pivot Green Stream Health Solutions Inc. (“PGS”).
Pivot Pharmaceuticals has a suite of 30 products ready for commercialization. The company also has a strong intellectual property (IP) portfolio for the formulation and delivery of cannabinoids. Pivot’s proposed product line comprises capsules and tablets, bulk powder, stick packs and beverages. Its product line also consists of water soluble oral solutions, lotions, creams, gels and pet supplements.
Pivot Pharmaceuticals has acquired the global rights for four proprietary drug delivery technologies. These technologies are for the delivery and commercialization of cannabinoid-, cannabidiol- and tetrahydrocannabinol-based products.
Researchers are continually working to design ways to breach the blood brain barrier. However, as an article in life sciences magazine The Scientist reported, “… researchers first have to understand it.” The article notes that researchers are working on techniques to bypass or sneak past the guardian of the central nervous system so they can better treat neurological disease.
Pivot Pharmaceuticals recently signed an option agreement with IP Med Inc. to acquire an exclusive global license for Trivair™ Nasal and Pulmonary Breath-Propelled Drug Delivery Systems™ for the delivery of Pivot’s Ready-To-Infuse-Cannabis (RTIC) cannabinoid products (http://nnw.fm/e4tWz). The TriVair™ Nasal device uses the body’s natural breath to drive a medication deep into the nasal cavity to targeted sites, bypassing the blood brain barrier and providing the potential to better treat central nervous system diseases.
Pivot’s PGS division has acquired the worldwide rights to the BiPhasix™ Transdermal Drug Delivery platform technology (topical). BiPhasix™ is a dermal delivery technology for cannabinoids. Moreover, 1% CBD BiPhasix Cream is ready for commercialization.
Additionally, PGS acquired the worldwide rights from Solmic GmbH (Germany) for the development and commercialization of the Solmic Solubilisation Technology Platform for defined cannabinoids or cannabinoid-containing extracts. This formulation technology offers considerably higher bioavailability and stability versus alternative oil-based formulations.
Pivot’s other technology platform is Thrudermic™, a transdermal nanotechnology for cannabinoids. Each of the company’s four technology platforms allows Pivot to produce numerous products.
Pivot Pharmaceuticals also recently signed an exclusive contract manufacturing agreement with Bio V Pharma Inc. (http://nnw.fm/tag3K). This agreement is for Bio V to manufacture, label, package and supply Pivot’s bio-cannabis product pipeline. Bio V, based in the Province of Quebec, is a full-service manufacturer of pharmaceutical and nutraceutical products. Bio V will produce Pivot Pharmaceuticals’ complete bio-cannabis family of products. This includes BiPhasix™ (topical creams and lotions), Thrudermic™ (transdermal gels and lotions), Solmic™ 1% CBD oral solution, and Ready-to-Infuse-Cannabis Powder.
In a news release, Dr. Patrick Frankham, chief executive officer of Pivot Pharmaceuticals, stated, “We are excited to have chosen Bio V Pharma as our Canadian manufacturing partner at this important time in Pivot’s history. Consumers and regulators will demand high-quality products that are manufactured in cGMP facilities by a knowledgeable and experienced team.”
For more information, visit the company’s website at www.PivotPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Pivot offers unique proprietary drug delivery platform technologies
- Company has a strong intellectual property (IP) portfolio for the formulation and delivery of cannabinoids
- Company acquires licensing rights to patented Trivair™ nasal and pulmonary drug delivery system, also signs exclusive manufacturing agreement with Bio V Pharma
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is a biopharmaceutical company based in Vancouver, British Columbia. Pivot engages in the development and commercialization of premium cannabinoid-based nutraceuticals and pharmaceuticals. It does so utilizing unique drug delivery platform technologies. Pivot Pharmaceuticals’ wholly-owned medical cannabis products division is Pivot Green Stream Health Solutions Inc. (“PGS”).
Pivot Pharmaceuticals has a suite of 30 products ready for commercialization. The company also has a strong intellectual property (IP) portfolio for the formulation and delivery of cannabinoids. Pivot’s proposed product line comprises capsules and tablets, bulk powder, stick packs and beverages. Its product line also consists of water soluble oral solutions, lotions, creams, gels and pet supplements.
Pivot Pharmaceuticals has acquired the global rights for four proprietary drug delivery technologies. These technologies are for the delivery and commercialization of cannabinoid-, cannabidiol- and tetrahydrocannabinol-based products.
Researchers are continually working to design ways to breach the blood brain barrier. However, as an article in life sciences magazine The Scientist reported, “… researchers first have to understand it.” The article notes that researchers are working on techniques to bypass or sneak past the guardian of the central nervous system so they can better treat neurological disease.
Pivot Pharmaceuticals recently signed an option agreement with IP Med Inc. to acquire an exclusive global license for Trivair™ Nasal and Pulmonary Breath-Propelled Drug Delivery Systems™ for the delivery of Pivot’s Ready-To-Infuse-Cannabis (RTIC) cannabinoid products (http://nnw.fm/e4tWz). The TriVair™ Nasal device uses the body’s natural breath to drive a medication deep into the nasal cavity to targeted sites, bypassing the blood brain barrier and providing the potential to better treat central nervous system diseases.
Pivot’s PGS division has acquired the worldwide rights to the BiPhasix™ Transdermal Drug Delivery platform technology (topical). BiPhasix™ is a dermal delivery technology for cannabinoids. Moreover, 1% CBD BiPhasix Cream is ready for commercialization.
Additionally, PGS acquired the worldwide rights from Solmic GmbH (Germany) for the development and commercialization of the Solmic Solubilisation Technology Platform for defined cannabinoids or cannabinoid-containing extracts. This formulation technology offers considerably higher bioavailability and stability versus alternative oil-based formulations.
Pivot’s other technology platform is Thrudermic™, a transdermal nanotechnology for cannabinoids. Each of the company’s four technology platforms allows Pivot to produce numerous products.
Pivot Pharmaceuticals also recently signed an exclusive contract manufacturing agreement with Bio V Pharma Inc. (http://nnw.fm/tag3K). This agreement is for Bio V to manufacture, label, package and supply Pivot’s bio-cannabis product pipeline. Bio V, based in the Province of Quebec, is a full-service manufacturer of pharmaceutical and nutraceutical products. Bio V will produce Pivot Pharmaceuticals’ complete bio-cannabis family of products. This includes BiPhasix™ (topical creams and lotions), Thrudermic™ (transdermal gels and lotions), Solmic™ 1% CBD oral solution, and Ready-to-Infuse-Cannabis Powder.
In a news release, Dr. Patrick Frankham, chief executive officer of Pivot Pharmaceuticals, stated, “We are excited to have chosen Bio V Pharma as our Canadian manufacturing partner at this important time in Pivot’s history. Consumers and regulators will demand high-quality products that are manufactured in cGMP facilities by a knowledgeable and experienced team.”
For more information, visit the company’s website at www.PivotPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)